Literature DB >> 17917586

Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis.

Elisabet Reyes-Irisarri1, Antonio J Sánchez, Juan Antonio García-Merino, Guadalupe Mengod.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) in Lewis rats is the most widely used animal model for multiple sclerosis. Cyclic adenosine monophosphate (cAMP) has been associated with neuroinflammation. The aim of this study was to investigate the possible involvement of different cAMP-specific phosphodiesterase (PDE) isoenzymes by analyzing their expression in the brain of EAE rats. We found in the brain of EAE animals that there was a dramatic increase in the mRNA expression levels of the PDE4B isozyme detected around blood vessels from the spinal cord to the upper midbrain. There was a single splicing form of the 4 splice variants that are known for PDE4B: PDE4B2, which showed increased expression levels. This overexpression is localized around the blood vessels and parenchyma in infiltrating T cells and macrophages/microglia. These results support the role played by the activation of the PDE4B2 gene in the neuroinflammatory process in EAE rats.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917586     DOI: 10.1097/nen.0b013e3181567c31

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  12 in total

Review 1.  Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.

Authors:  David J Titus; Anthony A Oliva; Nicole M Wilson; Coleen M Atkins
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

2.  Postinjury treatment with rolipram increases hemorrhage after traumatic brain injury.

Authors:  C M Atkins; Y Kang; C Furones; J S Truettner; O F Alonso; W D Dietrich
Journal:  J Neurosci Res       Date:  2012-04-26       Impact factor: 4.164

3.  Phosphodiesterase isoform-specific expression induced by traumatic brain injury.

Authors:  Anthony A Oliva; Yuan Kang; Concepcion Furones; Ofelia F Alonso; Olga Bruno; W Dalton Dietrich; Coleen M Atkins
Journal:  J Neurochem       Date:  2012-11-01       Impact factor: 5.372

4.  Effects of early rolipram treatment on histopathological outcome after controlled cortical impact injury in mice.

Authors:  Coleen M Atkins; Maria L Cepero; Yuan Kang; Daniel J Liebl; W Dalton Dietrich
Journal:  Neurosci Lett       Date:  2012-10-26       Impact factor: 3.046

5.  Proinflammatory cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling in microglia in vitro and following CNS injury.

Authors:  Mousumi Ghosh; Daniela Garcia-Castillo; Vladimir Aguirre; Roozbeh Golshani; Coleen M Atkins; Helen M Bramlett; W Dalton Dietrich; Damien D Pearse
Journal:  Glia       Date:  2012-08-02       Impact factor: 7.452

Review 6.  Opioids and infections in the intensive care unit should clinicians and patients be concerned?

Authors:  Craig R Weinert; Shravan Kethireddy; Sabita Roy
Journal:  J Neuroimmune Pharmacol       Date:  2008-09-05       Impact factor: 4.147

7.  Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival.

Authors:  E M Medina-Rodríguez; F J Arenzana; J Pastor; M Redondo; V Palomo; R García de Sola; C Gil; A Martínez; A Bribián; F de Castro
Journal:  Cell Mol Life Sci       Date:  2013-05-10       Impact factor: 9.261

8.  The interplay between cyclic AMP, MAPK, and NF-κB pathways in response to proinflammatory signals in microglia.

Authors:  Mousumi Ghosh; Vladimir Aguirre; Khine Wai; Hady Felfly; W Dalton Dietrich; Damien D Pearse
Journal:  Biomed Res Int       Date:  2015-02-05       Impact factor: 3.411

9.  Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury.

Authors:  Nicole M Wilson; Mark E Gurney; W Dalton Dietrich; Coleen M Atkins
Journal:  PLoS One       Date:  2017-05-19       Impact factor: 3.240

10.  A Novel Catecholopyrimidine Based Small Molecule PDE4B Inhibitor Suppresses Inflammatory Cytokines in Atopic Mice.

Authors:  Baskaran Purushothaman; Parthasarathy Arumugam; Joon Myong Song
Journal:  Front Pharmacol       Date:  2018-05-11       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.